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Purpose: To describe cancer prevalence and hospital service utilization by prevalent cancer patients in Western
Australia from 1992 to 2011.
Methods: This study was a population-based cohort study using the Western Australia (WA) Cancer Registry (1982
to 2011) as the source of incident cancer cases. These data were linked to mortality (1982 to 2011) and hospital
morbidity (1998 to 2011) records via the WA Data Linkage System to ascertain complete and limited-duration
prevalence and cancer-related hospitalizations over time. Prevalence rates were calculated using estimated
residential population data from the Australian Bureau of Statistics.
Results: In 2011, one in every 27 people living in WA had been diagnosed with cancer at some time in their
lifetime, and one in 68 had been diagnosed within the previous five years. Between 1992 and 2011, complete
cancer prevalence in Western Australia increased by a magnitude of 2.5-fold. Forty-five and 44% of the increase in
complete cancer prevalence in males and females between 1992 and 2011 can be attributed to prostate and breast
cancer, respectively. The absolute number of cancer-related bed days increased 81 and 74% in males and females,
respectively, diagnosed within one year, between 1998 and 2011.
Conclusions: The prevalence of cancer and the burden it places on hospitals continues to rise, demanding
ongoing efforts to prevent cancer through modifiable risk factors and better, more efficient use of health resources.
Steps should to be taken to understand and address overdiagnosis and overtreatment.
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Cancer is the leading cause of burden of disease in
Australia as measured by mortality and disability [1] and
the sixth-most expensive chronic disease, with cancer
diagnosis, treatment, and care accounting for 7% of total
health system expenditure [2]. While incidence and sur-
vival rates reported by cancer registries provide valuable
information to assess the cancer burden and guide
health system planning, they alone do not provide a
complete picture of cancer in the community, and tend
to focus on the burden of cancer within the first few
years of diagnosis. As more people are living with and
beyond cancer, cancer prevalence, the absolute number
of people living in the community who have been
diagnosed with cancer, [3,4] has become increasingly* Correspondence: Susannah.maxwell@curtin.edu.au
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unless otherwise stated.valuable for health service planning [4,5], just as it is for
other chronic diseases such as diabetes. This is particu-
larly so for long-term survivors (those who are at least
five years beyond their diagnosis with a low chance of
recurrence [6,7]), who have different health service
needs due to the risk of late and long-term adverse
effects of cancer treatment [6].
Prevalence can be “complete,” representing all in-
dividuals who have ever had a diagnosis of cancer, or of
“limited duration,” describing the absolute number of
individuals alive within a specified time period since
diagnosis (such as for those diagnosed within five or
10 years). Limited duration prevalence can provide a
convenient measure given the limited surveillance period
of cancer registries, but it also recognizes the different
stages of cancer management, with time since diagnosis
being a reasonable indicator of phase of cancer care,
from acute care following diagnosis through palliativel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Leukaemias (all) 9800-9801, 9805, 9836–9837, 9823, 9820, 9826,
9827, 9831–9834, 9840, 9861, 9866–9867,
9870–9874, 9891, 9895-9897, 9910, 9920,





Lung, bronchus, trachea C33
Lymphomas (all) 9590, 9650–9667, 9670–9671, 9673, 9675,
9678–9680, 9684, 9687, 9689–9691, 9695,
9698–9699,9766, 9700–9702, 9705, 9708–9709,
9714, 9716, 9717–9719, 9727–9729, 9591,
9596–9599,* 9687
Melanoma C44; M-8720-8790









*male only **female only.
ICD-0–3 codes: *9597, *9598 and *9599 are Western Australian Cancer Registry
codes for not otherwise specified non-Hodgkin Lymphoma which can be
grouped as low, intermediate, or high grade, respectively, but which would
only be otherwise placed in the ICD-O classification as code 9591.
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Prevalence can be estimated indirectly by modeling
incidence, mortality, and survival data; however, more
precise estimates can be gained with a direct method [9]
using data on incident cases and death records to deter-
mine the number of individuals remaining alive at a
certain point in time.
In Australia all cancer, with the exception of nonmela-
noma skin cancer, is a notifiable disease. Cancer diagnoses
are reported to the State Cancer Registry in Western
Australia (WA), which provides annual population-based
incidence and cancer-related mortality statistics [10].
Prevalence of cancer in WA has not been directly esti-
mated since a 2002 study, which reported annual pre-
valence of cancer from 1990 to 1998 [4]. In this paper we
directly estimate and describe trends in the size and com-
position of the cancer-prevalent population by cancer type
and time since diagnosis between 1992 and 2011, as well
as hospitalization trends of prevalent cases between 1998
and 2011. These data will allow health services to better
allocate their resources and tailor activities to meet the
needs of this population.
Methods
This study was a population-based cohort study using
the WA Cancer Registry (1982 to 2011) as the source of
incident cancer cases. These data were linked to mor-
tality (1982 to 2011) and hospital morbidity (1998 to
2011) records via the WA Data Linkage System [11] to
ascertain person prevalence and cancer-related hospital
service utilization in prevalent cases.
Incident cases were identified from 1 January 1982 to
31 December 2011 inclusive on the basis of tumour site
code, morphology code, and behavior type. The study
was restricted to people who were identified as residents
of WA on their cancer registry record. Only invasive pri-
mary tumors were selected, with metastases from a pre-
vious primary tumour and benign and in situ neoplasms
excluded. Where more than one record of the same can-
cer occurred in the same individual the earliest record
was used as the incident case for that individual. Mul-
tiple records pertaining to different cancer types were
not considered. Analyses were also conducted according
to the type of cancer using the International Classifi-
cation of Diseases for Oncology codes provided in the
cancer registry data [12,13]. The types of cancer in-
cluded were those commonly reported separately in the
cancer incidence and mortality in Western Australia
reports and are shown in Table 1.
The point prevalence of cancer was calculated at 30
June of each year (1992 to 2011) counting the number
of incident cases diagnosed prior to this date who were
not known to have died (using a combination of WA
mortality records and the death indicator on the WAcancer record where available) as prevalent cases. Complete
prevalence was calculated for males and females as well as
limited duration prevalence [14] for those up to one year
postdiagnosis, at one to five years, and at five to 10 years
postdiagnosis for all cancers (Table 1). Rates were calcu-
lated using the number of persons resident in Western
Australia at that time from the Australian Bureau of
Statistics [15] as the denominator.
Correction for underascertainment due to start of WA
Cancer Registry
Since cancer diagnoses have only been recorded on the
WA Cancer Registry since 1 January 1982, there was
likely to be underascertainment of complete prevalence,
especially in the early years. To estimate the number of
cancer diagnoses underascertained it was assumed that a
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dividuals in 2011) provided a true estimate (and thus the
full count of the prevalence) of the number of individ-
uals living with cancer.
The corrected number of prevalent individuals in the
early years was estimated by (i) calculating the propor-
tion of the true number of individuals that would have
been estimated in 2011 using incrementally shorter (by
one year) look-back periods and (ii) applying the appro-
priate proportion determined in part (i) to the preva-
lence calculated for look-back periods less than 29 years
as shown in equation 1 below.




Where CP = Corrected Prevalence, P = Prevalence,
X = the year to be corrected, and Y = the number of
years of look-back data available for year X.
The number of years of look-back (one to 29) and the
calendar years (1982 to 2011) were then used to create a
table of cumulatively adjusted correction factors for each
year. These correction factors, together with the preva-
lence derived from the WA Cancer Registry data, were
used to provide a corrected estimate of the prevalence of
cancer for each year of the study. This correction was
undertaken for all invasive cancers and for each type of
cancer separately for each gender.
Data for complete prevalence and limited-duration
prevalence for persons more than 10 years postdiagnosis
are reported using these corrected estimates. Data pre-
sented for the remaining limited duration prevalence
windows did not require correction.
Hospitalizations
Linked hospital records were considered relevant to the
treatment of cancer if they contained a principal diagno-
sis of the cancer under investigation or they contained
procedure codes relating to chemotherapy or radiothe-
rapy. The cumulative and average number of bed days
and admissions per prevalent male and female up to one
year postdiagnosis, at one to five years, and five to
10 years postdiagnosis were calculated using the number
of prevalent individuals as the denominator.
This study was approved by the Western Australia
Department of Health, Human Research Ethics Committee,




In 2011, 37.6 per 1,000 males (one in 27) and 36.5 per
1,000 females (one in 27) living in WA had a history of
cancer, and 16.4 (one in 61) and 12.8 (one in 78) had
been diagnosed within the previous five years (Table 2).Between 1992 and 2011, complete cancer prevalence
increased by 29,985 males and by 23,953 females, re-
presenting a 2.5-fold increase in the estimated absolute
number of surviving individuals who had ever been diag-
nosed with cancer in WA (Figure 1). During this time,
the WA resident population increased by only 40% [15].
Over the same time period the absolute number of
males and females alive more than 10 years postdiag-
nosis increased by 3.4- and 2.5-fold, respectively. The
mix of cancer cases in the community by time since
diagnosis has changed somewhat over time, with long-
term survivors (more than five years since diagnosis)
contributing 56% of all prevalent males and 65% of
prevalent females in 2011, compared to 50% and 59% in
1992 (Table 2).
For the majority of cancers, the complete prevalence
rate increased linearly in both males and females; how-
ever, rates of cancer of the cervix, stomach, and bladder
decreased (Figure 2). The prevalence of prostate cancer
increased rapidly in the early 1990s, plateaued, and then
steadily increased (Figure 2). The complete prevalence
rate of lung cancer showed a small decrease in males
(0.62 to 0.56 per 1,000) and a steady increase in females
(0.26 to 0.45 per 1,000). Similar trends were seen for
other periods since diagnosis (data not shown). Of the
less-prevalent cancers (<2 per 1,000) the most dramatic
relative changes in prevalence for males and females
between 1992 and 2011 were for cancers of the liver,
thyroid, and kidney (Figure 3). Forty-five and 44% of the
increase in complete cancer prevalence in males and
females between 1992 and 2011 can be attributed to
prostate and breast cancer, respectively (Figure 3).
Cancer-related hospitalizations
The number of total bed days per prevalent case re-
mained relatively constant between 1998 and 2011, with
a slight downward trend in males; however, over the
study period, the absolute number of bed days increased
81 and 74% in males and females diagnosed within one
year, respectively (Figure 4). The population increased by
30% over this time. The number of bed days per preva-
lent individual varied by time since diagnosis, with males
and females within a year of diagnosis having an average
of 10.5 and 12.1 bed days, respectively, in 2011. For
those diagnosed between one and five years and between
five and 10 years earlier, annual bed days dropped sig-
nificantly, with 4.4 male and 4.5 female bed days and 3.6
male and 3.2 female bed days, respectively. The pro-
portion of prevalent cases with a cancer-related hospital
admission in 2011 also decreased with duration of pre-
valence (Figure 5), as did the proportion with more than
one hospital admission within a year. Forty-seven and
42% of the 2011 prevalent males and females, res-
pectively, who had ever been diagnosed with cancer
Table 2 Complete, limited-duration, and specific cancer site prevalence per 1,000 males and females, 1992 and 2011
Per 1,000 (proportion**)
1992 2011 Relative change
Males Complete prevalence* 17.4 37.6 2.2
Duration >10 years* 4.8 (28%) 11.6 (31%) 2.4
5–10 years 3.8 (22%) 9.6 (26%) 2.5
1–5 years 6.0 (35%) 12.2 (32%) 2.0
Up to 1 year 2.7 (16%) 4.2 (11%) 1.5
Cancer site* Prostate 3.0 (17%) 13.5 (36%) 4.5
Melanoma 3.7 (21%) 7.0 (19%) 1.9
Colorectal 2.6 (15%) 4.5 (12%) 1.7
Females Complete prevalence* 22.71 36.5 1.6
Duration > 10 years* 8.3 (36%) 14.7 (40%) 1.8
5–10 years 5.0 (22%) 9.0 (25%) 1.8
1–5 years 6.9 (30%) 9.5 (26%) 1.4
Up to 1 year 2.5 (11%) 3.3 (9%) 1.3
Cancer site* Breast 7.6 (34%) 14.4 (39%) 2.7
Melanoma 4.1 (18%) 6.0 (16%) 2.1
Colorectal 2.6 (12%) 3.8 (10%) 2.1
*Complete prevalence rates and rates of prevalence in those at 10 years or more postdiagnosis are corrected prevalence estimates. Cancer site data are for
complete prevalence.
**Relates to the proportion of complete cancer prevalence accounted for by each subset of cancer prevalence (limited duration or cancer site).
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hospital admission in 2011, with 27 and 23% having
more than one admission (data not shown).
Discussion
Since the early 1990s the number of people living in
Western Australia with a history of cancer has increased
by a magnitude of 2.5-fold, easily outpacing population
growth. The majority of these individuals have been
living with cancer – or beyond cancer– for more than
five years, and were diagnosed with prostate, breast,
melanoma, or colorectal cancer, which cumulatively ac-
count for two-thirds of all cancers. Cancer prevalence in
WA and the mix of types of cancer are similar to those
reported in a global study, with one in every 60 to 70
people living in the United States, Australia, and Europe
having had a cancer diagnosis with the previous five
years and breast and prostate carcinomas being the most
prevalent cancers. The relative prevalence of melanoma
stands out in WA, with a prevalence that surpasses that
of colorectal cancer, the second-most prevalent cancer
globally and third-most prevalent cancer in men and
women in WA in 2011 [16,17].
Understanding the increase in prevalence
While the drivers for the increase in prevalence are both
incidence and survival, a 2013 comparative analysis of
cancer statistics in the United States, Italy, Nordic coun-
tries, Australia, and France found variation in prevalencerates between countries to be more strongly associated
with incidence [16,17]. We found the majority of the
increase in cancer prevalence in males and females to be
due to prostate and breast cancers, respectively, much of
which may be explained by increasing incidence of these
cancers [1] in an aging population but also improved
survival following earlier detection and advances in
medical treatment. The “hump” seen in the prevalence
of prostate cancer in the 1990s (Figure 2A) may be ex-
plained by the increased diagnosis of prostate cancer
after the prostate-specific antigen (PSA) test became
available in the late 1980s [18] and actively promoted in
the early-to-mid 1990s [19]. In the longer term, assum-
ing screening is not leading to overdiagnosis – “the diag-
nosis of a cancer that would otherwise not go on to
cause symptoms or death” [20] – screening should have
little impact on incidence. The PSA test however, has
been shown to overdiagnose prostate cancer, with one
study reporting overdiagnosis as high as 84% [18,20].
Notably, a 2002 comparative study of prostate cancer
prevalence rates in Europe concluded that much of the
variation in prevalence was likely to be due to differen-
tial uptake of PSA testing [8]. Screening mammography
for breast cancer, introduced nationally in Australia in
the early 1990s, has also been shown to overdiagnose
cancer, particularly ductal carcinoma in situ [21,22]. A
2014 paper quantified the extent to which overdiagnosis
may occur, reporting that among 40-, 50-, and 60-year-
old women undergoing annual mammography over
Figure 1 Complete and limited-duration prevalence in males and females, 1992–2011. Figure 1 shows the cumulative prevalence for all
cancers for males (A) and females (B) between 1992 and 2011 by time since diagnosis; up to one year, one to five years, five to 10 years, and
more than 10 years. The table immediately below the chart lists the absolute prevalence numbers for 2011, along with the absolute and relative
change in cancer prevalence and the WA population between 1992 and 2011.
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respectively, would be overdiagnosed and needlessly
treated [23]. The magnitude to which overdiagnosis, also
reported in other cancers including thyroid cancer and
melanoma [20], has increased cancer prevalence is
unknown, but raises concerns of unnecessary medical
treatment – and associated harms– in an increasingly
burdened health system.
The large relative increase in the prevalence of thyroid
cancer, consistent with a marked increase in incidence
globally over the past 40 years, is thought to be due to
the incidental discovery of nodules during ultrasound
for unrelated conditions, as well as changes in diagnostic
thresholds [24]. Incidence also explains the rise in the
prevalence of liver cancer, although survival has also
improved [14]. Lung cancer, accounting for around 9% of
all incident cancer cases, is a comparatively less-prevalent
cancer due to its high mortality rate, representing 19% of
all cancer deaths in 2009 [1]. The prevalence of lung
cancer increased in women, while in men it showed aslight downwards trend, reflecting changes in the inci-
dence of lung cancer, mirroring smoking trends in men
and women 30 to 40 years ago [25]. Decreasing trends in
both cervical and bladder cancer reflect falling incidence;
however, the change in cervical cancer has occurred as a
result of a successful screening program to detect and
treat precancerous changes, while the fall in bladder can-
cer incidence is largely attributed to changes in coding,
complicating the interpretation of trends [14].
Health service needs of prevalent individuals
The rising prevalence of cancer translates into a growing
burden on hospitals, with a 70 to 80% increase in the total
number of cancer-related hospital bed days over 13 years,
more than twice the relative population growth. As ex-
pected the demand on health services is highest in those
accessing acute cancer care services within one year of
diagnosis; however, we found that more than a third of
prevalent individuals were still accessing cancer-related
hospital services for their primary cancer more than
Figure 2 Complete prevalence rates in males and females for selected cancers, 1992–2011. These figures are based on complete corrected
prevalence estimates.
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lent cases having at least one cancer-related hospitalization
within a year. While not all cancer services are delivered
in hospital, this measure of hospital service use could be
considered a surrogate measure of “active” prevalence,
that is, cancer cases requiring ongoing treatment. In 2002,
Brameld et al. estimated that 25% of prevalent individuals
in 1998 were “active;” this is significantly lower than our
estimate, however the Brameld et al. calculation was based
on the proportion of patients that die from their cancer, a
method the authors accepted would underestimate the
need for ongoing health care [4]. Furthermore, Brameld
used more complex analytic methods to estimate com-
plete prevalence due to the shorter look-back period and
therefore results may not be comparable [4]. These
high rates of active prevalence (30 to 40% of completeprevalence) even in individuals more than 10 years after
diagnosis reinforce cancer as a chronic disease.
The changing health needs of prevalent cases go beyond
hospital care to monitoring and surveillance and the man-
agement of long-term and late effects from cancer care.
Many people living beyond cancer face physical and psy-
chological long-term and late effects of their cancer; the
most commonly reported include fatigue, sexual dysfunc-
tion, decreased participation in activities, and musculos-
keletal problems [7]. The type and extent of effects vary by
the type of cancer, treatment, and age. Previous reports
also cite poorer management of comorbidities, including
diabetes and cardiovascular disease in cancer survivors
compared to the nonprevalent population. Primary care
services will be increasingly relied upon to provide holistic
management for the growing body of cancer survivors [26].
Figure 3 Change in complete cancer prevalence for males and females by cancer site, 1992–2011. These figures are based on complete
corrected prevalence estimates. The bars indicate the relative change in the complete prevalence of each cancer between 1992 and 2011.
Population growth is shown by the black bar. Where the relative change in the cancer is less than the relative change of the population
(indicated by the black line), the prevalence rate has decreased. The numbers in brackets indicate the absolute number of additional cases
since 1992.
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The extent to which cancer hospitalization data reflect
hospital cancer service use depends on coding and ad-
ministrative practices. In WA, but not in all Australian
jurisdictions, the majority of chemotherapy patients are
classified as admitted patients, while the majority of
radiotherapy patients are nonadmitted (outpatients) as
they are throughout Australia [27,28]. As such, our
cancer-related hospitalization data will include most
chemotherapy but not radiotherapy services. This is a
significant limitation, with around 35% of all cancer
patients accessing radiation services at some time during
their illness [29]. In addition, our measure of active
prevalence does not reflect the proportion of prevalentcases requiring ongoing cancer services outside the hos-
pital system. Many individuals are likely to continue to
access pharmacological, adjuvant, palliative, and primary
care services as a result of their cancer in the absence of
a hospital admission.
The precision of our results also depends on the integ-
rity of the cancer and hospital morbidity data, as well as
the migration of individuals out of the state. Under-
reporting of cancer cases has the potential to underesti-
mate prevalence, while loss to follow-up due to migration
may overestimate survival and therefore prevalence. Ad-
ditionally, our study was limited to individuals resident in
WA at the time of their cancer diagnosis, with individuals
who migrated into the state included in population
Figure 4 Bed days per individual (C/D) and total annual bed days (A/B) in males and females in 2011 by time since diagnosis.
Figure 5 Proportion of prevalent individuals with a cancer-related hospitalization in 2011 by time since diagnosis.
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potentially underestimating prevalence rates and cancer-
related bed days. Furthermore, the estimated complete
prevalence did not account for differential survival, as-
suming survival occurred as per 2001 rates, effectively
overestimating prevalence rates in the early years.
Our corrected estimates for complete prevalence
assumed a 29-year look-back to be sufficient. This is
consistent with Capocaccia and De Angelis, who found a
30-year look-back period provided acceptable prevalence
estimates in populations where the average age of preva-
lent cases is quite high [9]. However, a small underascer-
tainment bias may remain for cancers with high survival
and relatively earlier age of occurrence (e.g., breast and
cervical cancer and cancers diagnosed in childhood) [9].
While the technique to adjust prevalence is simplistic, it
is appropriate for data where full capture is available but
would not be suitable for data where the longest look-
back period does not infer full capture. In such cases a
more complex algorithm would be required based on
relative survival in the population concerned.
Conclusion
Our data paint a bleak picture of steadily increasing
prevalence and cancer burden on hospital services, be-
yond population growth; a demand that is in part due to
success in improving cancer survival and general life ex-
pectancy in the community. To stall trends in prevalence
rates in an aging population, continued efforts are re-
quired to prevent cancer through modifiable risk factors,
as has been achieved to some extent with lung cancer in
males. Furthermore, rising prevalence will continue to
demand better use of health resources. Steps should be
taken to address and understand the extent of cancer
over diagnosis, particularly of prostate cancer, and its
impact on prevalence and cancer service use. In the lon-
ger term, developments in genomics may allow for bet-
ter targeted screening and more accurate predictions of
tumor behavior that mitigate overdiagnosis and prevent
overtreatment [20,30]. Additionally, our data highlight
the need for the consideration of cancer services beyond
acute care, meeting the needs of the thousands of indi-
viduals facing long-term adverse outcomes from cancer
treatment, particularly for those most prevalent cancers.
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